Wound healing progresses through hemostasis, inflammation, proliferation, and remodeling — requiring coordinated angiogenesis, fibroblast activation, collagen synthesis, and immune regulation. Chronic wounds (diabetic ulcers, pressure sores, surgical wounds) fail due to impaired angiogenesis, excessive inflammation, or inadequate fibroblast response. Peptide research accelerates every phase of the healing cascade.
1. BPC-157 — Master Wound Healing Peptide
BPC-157 accelerates wound healing through multiple simultaneous mechanisms: promoting VEGF-driven angiogenesis (critical for wound oxygenation), stimulating fibroblast migration and proliferation, reducing inflammatory cytokines that delay healing, and upregulating growth hormone receptors at wound sites. It has demonstrated efficacy across skin wounds, muscle injuries, and deep tissue damage.
Dosing Protocol: 250–500 mcg SubQ daily, injected at wound margins for local delivery. Topical BPC-157 in solution or cream for surface wounds. Cycle: 2–6 weeks depending on wound severity.
2. GHK-Cu — Collagen Architecture / Angiogenesis
GHK-Cu drives organized collagen deposition in healing wounds, preventing the disorganized scar collagen that produces cosmetically and mechanically inferior healed tissue. It simultaneously promotes wound angiogenesis, activates MMP-driven removal of damaged extracellular matrix, and stimulates keratinocyte migration for re-epithelialization.
Dosing Protocol: Topical: 0.5–2% GHK-Cu applied directly to wound after cleansing 1–2x daily. Systemic: 1–2 mg SubQ daily. Topical is primary for wound healing applications.
3. TB-500 — Cell Migration / Anti-Adhesion
Wound healing requires rapid migration of fibroblasts, endothelial cells, and keratinocytes to the wound site. TB-500 promotes actin-mediated cell migration, dramatically accelerating the arrival of repair cells at the wound. It also reduces the inflammatory adhesions and wound contracture that produce stiff, restricted scar tissue.
Dosing Protocol: 2 mg SubQ twice weekly during active wound healing. Reduce to once weekly once wound is closed. Stack with BPC-157 for synergistic effects.
4. KPV — Wound Inflammation Control
Excessive wound inflammation — particularly relevant in diabetic wounds and chronic ulcers — impairs healing by maintaining the destructive inflammatory phase. KPV targets NF-κB in wound macrophages and dermal cells, resolving the chronic inflammatory state that keeps wounds in the inflammatory phase rather than transitioning to productive repair.
Dosing Protocol: 200–500 mcg SubQ daily near wound site, or topical KPV in cream for direct wound application. Cycle: 4–6 weeks.
BPC-157 drives angiogenesis and growth factor signaling across the entire wound. GHK-Cu ensures newly deposited collagen is organized and architecturally sound. TB-500 accelerates cell migration to the wound — the rate-limiting step in healing. KPV resolves the chronic inflammation that stalls wounds in the inflammatory phase and prevents transition to productive repair.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).